secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001104659-24-075722
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Alvogen terminates NRX-101 pact; NRx eyes accelerated FDA filing
----------------------------------------------------------------

- Alvogen terminated exclusive development and license agreement for NRX-101 effective June 21, 2024.
- Alvogen claims $4,502,705 in advanced amounts; parties to negotiate royalty within 30 days.
- NRx plans Accelerated Approval filing this year for suicidal bipolar depression, citing trial data.
- Company continues NDA submission for intravenous ketamine (NRX-100) in 2024.
- NRx estimates $3.7B addressable market for NRX-101 in high-risk patients without viable alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924075722/0001104659-24-075722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924075722/tm2418373d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-075722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer